3 assets in Schwannoma

Therapeutic assets addressing Schwannoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rvp-001 Schwannoma	Reveal Pharmaceuticals Inc.	P2	B (57)
Immunoglobulin G, Anti-(Human Calcitonin Gene-Related Peptide Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer Schwannoma	Massachusetts General Hospital	P2	CCC (53)
Siltuximab Schwannoma	Massachusetts General Hospital	P2	CCC (53)